Summary
United States Patent 4,529,601, issued on July 16, 1985, to Eli Lilly & Co., primarily covers the chemical compound known as fluoxetine and its pharmaceutical compositions. The patent claims include the chemical structure, methods of synthesis, pharmaceutical formulations, and therapeutic applications. A review of the scope indicates broad claims covering fluoxetine or its pharmaceutically acceptable salts and methods for treating depression. The patent landscape reveals subsequent patents focused on derivatives, formulations, and specific medical indications, but the original patent has largely expired, opening the field for generic development.
What Does U.S. Patent 4,529,601 Cover?
Scope of the Claims
The patent’s claims broadly encompass the chemical class of selective serotonin reuptake inhibitors (SSRIs), focusing on fluoxetine. Key aspects include:
- Chemical structure: N-methyl-3-phenyl-3-[(α, α, α-trifluoromethyl)phenoxy]propylamine, specifically the racemic form of fluoxetine.
- Pharmaceutical compositions: Methods of preparing dosage forms with fluoxetine or its salts.
- Therapeutic applications: Use in treating depression, obsessive-compulsive disorder, and other psychiatric conditions.
The core claim (Claim 1) covers the compound itself:
“A compound selected from the group consisting of N-methyl-3-phenyl-3-[(α, α, α-trifluoromethyl)phenoxy]propylamine, and pharmaceutically acceptable salts thereof.”
Subsequent claims specify dosage forms, methods of synthesis, and specific salts like hydrochloride or citrate.
Claim Limitations and Broadness
- The claims do not extend to enantiomeric purity, encompassing the racemic mixture only.
- The scope covers any pharmaceutical composition containing fluoxetine, including various formulations and dosages.
- Use claims for treating depression are outlined but not necessarily broad, lacking explicit method claims specific to particular indications.
Patent Landscape and Related Patents
The patent landscape for fluoxetine includes both the original patent and multiple follow-up patents:
| Patent Number |
Filing Date |
Expiration |
Focus |
Notes |
| 4,529,601 |
Feb 8, 1983 |
July 16, 2002 |
Compound, synthesis, formulations |
Original patent on fluoxetine |
| 4,735,942 |
Aug 15, 1984 |
Jan 1, 2006 |
Method of treatment using fluoxetine |
Second patent with method claims |
| 5,254,781 |
Feb 26, 1993 |
2010 (expired) |
Use of fluoxetine for specific indications |
Expanded therapeutic use |
| 6,303,774 |
May 5, 1999 |
2016 |
Extended formulations, salts |
Patent on specific salt forms |
This portfolio indicates the core compound patent expired in 2002, but method-of-use patents and formulations, some extending beyond 2006, provided additional patent protection for specific clinical indications and delivery forms. Post-2006 patents are generally expired, enabling generic manufacture of fluoxetine.
Key Patent Rights and Limitations
- The original patent provided exclusive rights to the compound and its primary formulations until 2002.
- No patent claims extend to enantiomer-specific versions or cost-effective synthesis methods post-expiration.
- Use patents for specific indications like obsessive-compulsive disorder expired by 2010, opening pathways for broader indications.
- Recent formulations and salts such as sustained-release versions may still be patent-protected if filed subsequently.
Implications for Market and R&D
Patent Expiry and Market Entry
The expiration of US Patent 4,529,601 removes patent barriers for generic fluoxetine manufacturers. Market entry for generics occurred post-2002, resulting in significant price reductions. Brand companies have shifted focus to new indications, formulations, or combination therapies protected by later patents.
Patent Strategies and R&D Focus
Companies have pursued:
- Development of novel formulations (e.g., sustained-release) protected by new patents.
- Use of fluoxetine in combination therapies for treatment-resistant depression.
- Enantiomer-specific drugs (e.g., fluoxetine enantiomers) to circumvent expired patent claims and gain new market exclusivity.
Patent Challenges and Litigation
While the original patent expired, patent litigation has focused on method-of-use claims and formulation patents. Patent enforcement targeting generic manufacturers has waned, but some active patents protect newer formulations.
Conclusion & Key Takeaways
- US Patent 4,529,601 covers the chemical compound fluoxetine and basic formulations. It expired in 2002, opening the market for generics.
- The claims primarily protect the racemic mixture and general therapeutic use, with limited scope for enantiomer-specific or proprietary formulations.
- Post-expiration patent landscape includes patents on specific formulations, delivery methods, and therapeutic uses, but many have also expired.
- Ongoing R&D emphasizes novel delivery systems, combination therapies, and enantiomer-specific compounds to extend market exclusivity.
FAQs
1. What are the main claims in US Patent 4,529,601?
They cover the chemical structure of fluoxetine, its pharmaceutically acceptable salts, and methods for preparing pharmaceutical compositions containing the compound.
2. When did the patent expire, and what does that mean for generics?
The patent expired on July 16, 2002. It allowed generic manufacturers to produce and market fluoxetine without licensing restrictions from the patent owner.
3. Are there any current patents protecting fluoxetine formulations?
Most original formulation patents have expired. Recent patents focus on specific salts, delivery methods, or combination uses; however, many have also expired, reducing barriers for generics.
4. How have competitors extended patent protection beyond the original patent?
By filing patents for new formulations, specific therapeutic uses, and enantiomeric versions. These patents typically have shorter terms and can be circumvented with alternative approaches.
5. How does the patent landscape influence R&D efforts on fluoxetine?
It prompts development of proprietary formulations, combination therapies, and enantiomer-specific drugs to maintain market exclusivity against patent expiry.
References
- U.S. Patent 4,529,601, issued July 16, 1985.
- Food and Drug Administration (FDA) Drug Approval Data.
- Patent Landscape Reports on SSRIs.
- Patent No. 4,735,942 and others covering therapeutic methods and formulations.
- Market analysis articles on generic fluoxetine post-2002.
